When was Adaptimmune founded?

Adaptimmune was founded in 2008 and raised its 1st funding round 6 years after it was founded.

Where is Adaptimmune located?

Adaptimmune is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania.

Who is the current CEO of Adaptimmune?

Adrian Rawcliffe of Adaptimmune.

How many employees does Adaptimmune have?

As of Apr 30, 2026, the latest employee count at Adaptimmune is 158.

Is Adaptimmune a funded company?

Adaptimmune is a funded company, having raised a total of $104M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 25, 2014.

When was the latest funding round of Adaptimmune?

Adaptimmune's latest funding was a $***** Series A round on Sep 24, 2014, with participation from 12 investors.

What is the annual revenue of Adaptimmune?

Annual revenue of Adaptimmune is $178M as on Dec 31, 2024.

Where does Adaptimmune rank among its competitors?

Adaptimmune ranks 187th amongst 3300 active competitors, of which 1140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Adaptimmune?

Adaptimmune's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Adaptimmune - 2026 Company Profile, Team, Funding, Competitors & Financials

Adaptimmune is a public company based in Philadelphia (United States), founded in 2008. It operates as a Developer of novel cancer immunotherapies to treat cancer and infectious disease. Adaptimmune has raised $104M in funding from New Enterprise Associates. The company has 3300 active competitors, including 1140 funded and 789 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of novel cancer immunotherapies to treat cancer and infectious disease. The therapies aim to utilize the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor proteins (TCRs) as a means of strengthening natural patient T cell responses. Its lead TCR programs are against esophageal, multiple myeloma, melanoma which the company is developing in collaboration with GSK.

Website: www.adaptimmune.com/
Social
Registered Address: Philadelphia, Pennsylvania

Key Metrics

Founded Year

2008

Location

Philadelphia, United States

Stage

Public

Total Funding

$104M in 2 rounds

Latest Funding Round

Series A, Sep 24, 2014, $*****

Investors

New Enterprise Associates & 18 more

Ranked

187^th among 3300 active competitors

Annual Revenue

$178M as on Dec 31, 2024

Employee Count

158 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3140 more

Exit Details

Public

View Adaptimmune's full profile

Adaptimmune is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ADAPTIMMUNE THERAPEUTICS PLC CIN: (44)1235430000 , Belgium, Active	Dec 31, 2007	$178M (As on Dec 31, 2024)	449 (As on Dec 31, 2023)	-
ADAPTIMMUNE LLC CIN: 274919915 , United States, Active	Dec 31, 1999	-	270 (As on Dec 31, 2024)	-
Adaptimmune Limited CIN: 6456741 , United Kingdom, Active	Dec 18, 2007	-	-

Adaptimmune got listed on May 06, 2015.

Click here to take a look at Adaptimmune's IPO in detail

Adaptimmune has raised a total funding of $104M over 2 rounds. Its first funding round was on Mar 25, 2014. Its latest funding round was a Series A round on Sep 24, 2014 for $*****. 12 investors participated in its latest round. Adaptimmune has 19 institutional investors.

Here is the list of recent funding rounds of Adaptimmune:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 24, 2014	9949842	Series A	5516572	6795810	1647746	3360932
Mar 25, 2014	1174788	Grant (prize money)	9906944	2046111	2971092	Mrc

Access funding benchmarks and valuations. Sign up today!

View details of Adaptimmune's funding rounds and investors

Adaptimmune's employee count trend

Adaptimmune has 158 employees as of Apr 26. Here is Adaptimmune's employee count trend over the years:

Uncover Adaptimmune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adaptimmune include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Adaptimmune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
187th	Adaptimmune 2008, Philadelphia (United States), Public	Developer of novel cancer immunotherapies to treat cancer and infectious disease	$104M	Wellington, Orbimed & 17 others	60/100